GENE ONLINE|News &
Opinion
Blog

2021-08-11|

Novel Triple Immunotherapy Combo Rekindles Hope for Pancreatic Cancer Patients

by Isha Kapoor
Share To
Pancreatic cancer is the third-leading cause of cancer-related deaths in the US. Despite mammoth advancements in improving chemotherapeutic regimens, metastatic pancreatic adenocarcinomas still pose a greater clinical challenge due to dismal prognosis. However, MIT researchers now develop a novel triple immunotherapy combo that could potentially shrink or even eliminate pancreatic tumors.

GO Prime with only $1.49 now

LATEST
2025 Starts with a Jolt: Layoffs Hit the Life Sciences Industry Ahead of JPM
2025-01-16
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
Kate Middleton, Princess of Wales: Cancer Journey and Recovery
2025-01-15
What is Tech Giant NVIDIA Doing Now? Latest Collabs Building the Healthcare Puzzle, One Byte at a Time
2025-01-15
EY Predicts Smarter, Smaller M&A in Biotech and Pharma for 2025
2025-01-15
EVENT
2025-01-13
JP Morgan Healthcare Conference
San Francisco, California
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top